Evidence map›Paper›PMID 41374954›Full record

ArticleCancers2025

An Alternative Treatment Effect Measure for Time-to-Event Oncology Randomized Trials.

Alan D Hutson, Han Yu

Abstract read
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Alan D HutsonRoswell Park Comprehensive Cancer Center, Department of Biostatistics and Bioinformatics, Elm and Carlton Streets, Buffalo, NY 14623, USA.ORCID 0000-0002-7353-5650
Han YuRoswell Park Comprehensive Cancer Center, Department of Biostatistics and Bioinformatics, Elm and Carlton Streets, Buffalo, NY 14623, USA.

Funding

Statistics CoreU10CA180822 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Mei-Yin C Polley · 2014 to 2026
$146.4M
YAP1 and RB1 cooperate to regulate lung cancer lineage plasticity and therapeutic resistanceU24CA274159 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI DAVID W. GOODRICH, Alan David Hutson · 2022 to 2026
$8.5M
NCI NIH HHS U10 CA180822NCI NIH HHS U24 CA274159NIH HHS P30CA016056; U24CA305623; U24CA274159
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

martingale residualspermutation testproportional hazardsrandomization testsurvival analysis

Identifiers

PMID41374954
PMCPMC12691396

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.